SUPNSupernus Pharmaceuticals, Inc.
$42.68-7.3% 1Y
$42.68
$41.3152 weeks$57.00
SUPN in its own filings
SUPN's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
443
Events found in the filings · across 1,184 filings · the record starts in 2011
- Hard flags
- 3
Hard flags
- Most recent filing
- Aug 3, 2026
Most recent filing · Form 10-Q
- Record starts
- Jan 19, 2011
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Restatement admitted (non-reliance)historical
- 2016-11-14
- Change in certifying accountanthistorical
- 2015-10-15
- Late periodic report8 occurrences
- 2023-03-02
- Delisting notice / listing-rule failure3 occurrences
- 2022-03-21
- SEC comment-letter activity26 occurrences
- 2019-08-07
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026Filed by: Supernus Pharmaceuticals, Inc.Earnings release · press release
- Aug 3, 2026On August 3, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) published a post relating to the proposed merger of equals of the Company and Indivior Pharmaceuticals Inc. (“Indivior”) on the Company’s LinkedIn account.Other event · Form 8-K
- Aug 3, 2026As previously announced, on August 3, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) and Indivior Pharmaceuticals Inc. (“Indivior”) are hosting a conference call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger of the Company and Indivior.Other event · Form 8-K
- Aug 3, 2026Agreement and Plan of Merger On August 1, 2026 (the “Signing Date”), Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Supernus”), entered into a Merger Agreement (the “Merger Agreement”), by and among the Company, Indivior Pharmaceuticals Inc., a Delaware corporation (“Indivior”), and Artemis …Material agreement entered · Form 8-K
- Jul 22, 2026Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026.Earnings release · press release
- May 20, 2026On May 17, 2026 (the “Notice Date”), pursuant to the Contingent Value Right Agreement (the “CVR Agreement”) entered into as of July 30, 2025, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights …New debt or off-balance-sheet obligation · Form 8-K
- May 5, 2026Supernus Announces First Quarter 2026 Financial Results.Earnings release · press release
- Apr 22, 2026Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026.Earnings release · press release
- Apr 7, 2026Entry into Asset Purchase Agreement On April 1, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”), together with related ancillary transaction documents, with Navitor Pharmaceuticals, Inc., a Delaware corporation (“Navitor”), Navitor Pharmaceuticals, LLC, a …Material agreement entered · Form 8-K
- Feb 24, 2026Modification of Compensatory Arrangements with Executive Officers On February 18, 2026, the Compensation Committee (the “Committee”) of Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) recommended, and the Board of Directors (the “Board”) approved, modifications of the compensation of the Company’s …Director or officer change · Form 8-K
- Feb 24, 2026Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #21 of 41 by RyuScore